Nicoletta Colombo, European Institute of Oncology, Milan, Italy
Provided an on-site interpretation of the ENGOT-ov65 study at ESMO: Pembrolizumab combined with bevacizumab and chemotherapy significantly improved progression-free survival (PFS) in advanced ovarian cancer, with a manageable safety profile, offering new evidence for first-line immunotherapy in ovarian cancer!